RIVA – a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial

BACKGROUND: Over 12,000 new cases of B-cell malignancies are diagnosed in the UK each year, with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) being the most common subtypes. Standard frontline therapy consists of immunochemotherapy with a CD20 monoclonal antibody (mAb), such as...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Sean H., Linton, Kim M., Collins, Graham P., Dhondt, Joke, Caddy, Joshua, Rossiter, Liz, Vadher, Karan, Fines, Keira, Rogers, Laura E., Fernando, Diana, Stanton, Louise, Davies, Andrew J., Johnson, Peter W. M., Griffiths, Gareth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6230275/
https://www.ncbi.nlm.nih.gov/pubmed/30413184
http://dx.doi.org/10.1186/s13063-018-2996-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6230275/
https://www.ncbi.nlm.nih.gov/pubmed/30413184
http://dx.doi.org/10.1186/s13063-018-2996-6

Ejemplares similares